| __timestamp | Ionis Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 1271353000 |
| Thursday, January 1, 2015 | 322292000 | 1620577000 |
| Friday, January 1, 2016 | 344320000 | 2052295000 |
| Sunday, January 1, 2017 | 374644000 | 2075142000 |
| Monday, January 1, 2018 | 414604000 | 2186100000 |
| Tuesday, January 1, 2019 | 466000000 | 3036600000 |
| Wednesday, January 1, 2020 | 535000000 | 2735000000 |
| Friday, January 1, 2021 | 643000000 | 2908100000 |
| Saturday, January 1, 2022 | 833000000 | 3592500000 |
| Sunday, January 1, 2023 | 899625000 | 4439000000 |
| Monday, January 1, 2024 | 901530000 | 5132000000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. have demonstrated a steadfast commitment to advancing medical science. From 2014 to 2023, Regeneron's R&D expenses surged by an impressive 250%, peaking in 2023. This growth underscores their relentless pursuit of groundbreaking therapies. Meanwhile, Ionis Pharmaceuticals, known for its pioneering work in RNA-targeted therapeutics, increased its R&D spending by nearly 270% during the same period. The year 2023 marked a significant milestone, with Ionis investing almost 900 million dollars, reflecting their dedication to expanding their innovative pipeline. As these two biotech powerhouses continue to push the boundaries of science, their R&D investments highlight the critical role of sustained financial commitment in driving medical breakthroughs.
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Axsome Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Ionis Pharmaceuticals, Inc. vs Alkermes plc: Strategic Focus on R&D Spending
Ionis Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.